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The t(4;11)(q21;q23) translocation is associated with high-risk infantpro-B-cell acute lymphoblastic leukemia and arises prenatally duringembryonic/fetal hematopoiesis. The developmental/pathogenic con-
tribution of the t(4;11)-resulting MLL-AF4 (MA4) and AF4-MLL (A4M)
fusions remains unclear; MA4 is always expressed in patients with t(4;11)+
B-cell acute lymphoblastic leukemia, but the reciprocal fusion A4M is
expressed in only half of the patients. Because prenatal leukemogenesis
manifests as impaired early hematopoietic differentiation, we took advan-
tage of well-established human embryonic stem cell-based hematopoietic
differentiation models to study whether the A4M fusion cooperates with
MA4 during early human hematopoietic development. Co-expression of
A4M and MA4 strongly promoted the emergence of hemato-endothelial
precursors, both endothelial- and hemogenic-primed. Double fusion-
expressing hemato-endothelial precursors specified into significantly higher
numbers of both hematopoietic and endothelial-committed cells, irrespec-
tive of the differentiation protocol used and without hijacking survival/pro-
liferation. Functional analysis of differentially expressed genes and differen-
tially enriched H3K79me3 genomic regions by RNA-sequencing and
H3K79me3 chromatin immunoprecipitation-sequencing, respectively, con-
firmed a hematopoietic/endothelial cell differentiation signature in double
fusion-expressing hemato-endothelial precursors. Importantly, chromatin
immunoprecipitation-sequencing analysis revealed a significant enrichment
of H3K79 methylated regions specifically associated with HOX-A cluster
genes in double fusion-expressing differentiating hematopoietic cells.
Overall, these results establish a functional and molecular cooperation
between MA4 and A4M fusions during human hematopoietic develop-
ment.
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Introduction
The mixed-lineage leukemia (MLL) gene encodes for an
H3K4 histone methyltransferase important in hematopoi-
etic development.1 The human MLL gene is frequently
rearranged in acute leukemia and typically confers a dis-
mal outcome.2,3 Of particular interest is the
t(4;11)(q21;q23) translocation, which encodes the fusion
proteins MLL-AF4 (MA4) and AF4-MLL (A4M), and is
associated with infant B-cell acute lymphoblastic
leukemia (B-ALL). This t(4;11)+ infant leukemia is charac-
terized by a very brief latency, raising the question of how
it evolves so quickly.4 Moreover, the exceptionally high
concordance rate of t(4;11)+ B-ALL in monozygotic twin
infants5,6 suggests that all the necessary (epi)genetic events
required for leukemogenesis are accomplished prenatally,
during embryonic/fetal hematopoietic development.7
However, our understanding of t(4;11)-mediated develop-
mental effects is limited due, at least in part, to the variety
of phenotypes and long latency observed in currently
available t(4;11) mouse models.2,8-17 These different pheno-
types likely result from targeting a cell in the wrong devel-
opmental stage, or not addressing the impact of secondary
hits, leaving open questions about the developmental
impact of the t(4;11) translocation during early human
development. 
The functional and molecular contribution of the recip-
rocal fusion genes resulting from the derivative translocat-
ed chromosomes remains obscure in cancer. The MA4
fusion is always expressed in t(4;11)+ B-ALL patients,
whereas the reciprocal fusion A4M is expressed in only
half of the patients.18-20 Importantly, t(4;11)+ cell lines dis-
play addiction to MA4 but not to A4M,21,22 and although
A4M was not sufficient to initiate leukemia in cord blood-
derived CD34+ cells,23 it was nevertheless capable of initi-
ating B-ALL in mice without the requirement of MA4,
indicating that it contributes to t(4;11)-driven leukemoge-
nesis.11,24,25 Strikingly, a very recent clinical study has unrav-
eled an independent prognostic value for MA4 expression
in t(4;11)+ infant B-ALL, thus adding a new piece to the
puzzle.19 Thus, the developmental/pathogenic contribu-
tion of the t(4;11)– resulting reciprocal fusion A4M remains
enigmatic.
Human embryonic stem cells (hESC) represent a power-
ful tool for modeling different developmental aspects of
human disease that cannot otherwise be addressed by
analyses of patients’ samples or mouse models.7,26,27 Given
that prenatal leukemogenesis manifests as impaired early
hematopoietic differentiation, modeling hematopoietic
differentiation in hESC may represent a promising in vitro
approach to study the onset of hematopoiesis and the
mechanisms underlying early human hematopoietic
development.7 During hESC differentiation, a primitive
population of CD45– hemato-endothelial precursors (HEP)
arises and further differentiates into CD45+ hematopoietic
and mature endothelial cells.28-30 Beyond its pathogenic
role in acute leukemias, the MLL gene has also been impli-
cated in endothelial cell maturation,31 and endothelial dys-
function was recently linked to disease outcomes in child-
hood leukemias.32 We previously reported that MA4
favors the emergence of endothelial-primed HEP but not
hemogenic HEP from hESC.10 Here, we took advantage of
well-established hESC-based differentiation systems to
study whether the A4M fusion cooperates with MA4 dur-
ing early human hematopoietic and endothelial develop-
ment. We report a functional and molecular cooperation
between MA4 and A4M fusions, which results in
enhanced hemato-endothelial output during human
embryonic development.
Methods
Vector construction and lentiviral transduction
The cDNA for MA4 and A4M were subcloned into the pRRL-
EF1α-PGK-NEO vector.11,16 Both fusions have been described pre-
viously (Online Supplementary Figure S1A).11,23 We used the follow-
ing lentivectors containing either neomycin or dTo for cell selec-
tion: pRRL-EF1α-PGK-NEO (empty vector; EV), pRRL-EF1α-
MA4-PGK-NEO (MA4) and pRRL-EF1α-A4M-PGK-dTo (A4M).
VSV-G-pseudotyped lentiviral particles were generated in 293T
cells using standard transfection protocols and concentrated by
ultracentrifugation.33 hESC were infected overnight with concen-
trated EV or MA4 lentivirus plus 8 mg/mL polybrene. Viral super-
natants were washed away the next day, and EV- and MA4-trans-
duced hESC were then selected with G418 (50-100 μg/mL) for 3
weeks. For dual transduction of MA4 and A4M fusions, G418-
resistant MA4-expressing hESC were infected with A4M-express-
ing viruses. EV/G418-selected hESC were also transduced with
A4M alone. Transgene expression was confirmed for all the geno-
types (Figure 1).
Human embryonic stem cell culture and
characterization of transgenic human embryonic 
stem cell lines
hESC (AND1 cell line) were maintained undifferentiated on a
layer of irradiated human mesenchymal stem cells in complete
knockout Dulbecco modified Eagle medium containing 20%
knockout serum replacement and 8 ng/mL basic fibroblast growth
factor.34,35 The medium was changed daily, and cells were passaged
weekly by dissociation with 1:1 collagenase IV:dispase. Cultures
were visualized daily by phase contrast microscopy. Approval for
hESC work was obtained from the Spanish National Embryo
Ethical Committee. The pluripotency of transgenic hESC was
characterized by flow cytometry using antibodies against SSEA-3,
SSEA-4 TRA-1-60 and TRA-1-81 (BD Biosciences).36 Expression of
the pluripotency-associated transcription factors OCT4, NANOG,
SOX2, CRIPTO, and DNMT3B as well as transgene expression
(MA4 and A4M) were analyzed by quantitative real-time poly-
merase chain reaction (PCR) (Online Supplementary Table S1 shows
the primers and PCR conditions used).23,37,38
Hematopoietic differentiation from human embryonic
stem cells by embryoid body formation
Undifferentiated hESC were treated with collagenase IV:dispase
for 1 h at 37ºC. To examine embryoid body (EB) formation, cells
were transferred to low-attachment plates and incubated
overnight in differentiation medium (knockout Dulbecco modi-
fied Eagle medium supplemented with 20% fetal bovine serum,
1% non-essential amino acids, 1 mmol/L L-glutamine, and 0.1
mmol/L b-mercaptoethanol). The medium was changed the next
day to the same differentiation medium supplemented with the
following hematopoietic cytokines: 300 ng/mL stem cell factor,
300 ng/mL Flt3L, 10 ng/mL interleukin-3, 10 ng/mL interleukin-6,
50 ng/mL granulocyte - colony-stimulating factor and 25 ng/mL
bone morphogenetic protein-4 (all from R&D).9,29,39-41 EB were dis-
sociated at different time points during development using colla-
genase B and enzyme-free Cell Dissociation Buffer (Invitrogen).
Dissociated cells were stained with anti-CD34-PE, anti-CD31-
FITC, anti-CD45-APC or anti-CD34-PE-Cy7, CD31-BV510, anti-
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glycophorin A, anti-CD43-FITC, anti-CD45-APC antibodies (all
from BD Biosciences) and 7-actinomycin D, and analyzed using a
FACS Canto flow cytometer.9,29,39-41 Colony-forming unit assays
were performed on days 10 and 15 of EB differentiation by plating
60x104 EB cells onto serum-free methylcellulose H4435 (Stem Cell
Technologies). Colonies were scored after 12 days.9,29,42-44
Cell cycle and apoptosis analysis 
For cell cycle analysis of hESC-derived HEP and CD45+ cells,
day 15 EB were dissociated and harvested cells were fixed
overnight in 70% ice-cold ethanol. Cells were then washed in
phosphate-buffered saline and incubated with anti-CD31-FITC,
anti-CD34-PE-Cy7 and anti-CD45-APC antibodies for 15 min.
Cells were then suspended in propidium iodide-containing buffer
and acquired and analyzed on a FACS Canto-II using Modfit LT4.0
software, discriminating between quiescent cells (G0/G1), cycling
cells (S-phase) and G2/M cells.45,46 Apoptosis was assessed with an
Annexin-V Apoptosis Detection kit (BD Biosciences).16
Human embryonic stem cell-OP9 co-cultures
hESC-OP9 co-cultures were performed as described else-
where.47,48 OP9 stroma was prepared by plating OP9 cells in gela-
tin-coated dishes, and allowing them to overgrow as a monolayer.
hESC were prepared as a suspension of small aggregates using col-
lagenase IV:dispase. One-tenth of this suspension was plated on
top of the 8-day overgrown OP9 stroma. Media were replaced on
AF4-MLL in human embryonic hematopoietic development
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Figure 1. Characterization of transgenic
human embryonic stem cells expressing the
reciprocal fusion A4M together with MA4. (A)
RNA-sequencing and quantitative real-time
polymerase chain reaction (qRT-PCR) valida-
tion revealed that ~45% (11/25) of the
patients with t(4;11)+ B-cell precursor acute
lymphoblastic leukemia do not express the
reciprocal fusion A4M.18 (B) Left, Phase-con-
trast morphology of representative colonies
from each transgenic human embryonic stem
cell (hESC) line. Right, Reverse transcriptase
polymerase chain reaction analysis (RT-PCR)
confirming expression of both fusions in undif-
ferentiated hESC. (C) qRT-PCR expression of
the pluripotency genes OCT4, SOX2, NANOG,
CRIPTO, and DNMT3B. (D) Representative
FACS data confirming expression of the pluripo-
tency surface markers SSEA-3, SSEA-4, TRA-1-
60, and TRA-1-81. BCP-ALL: B-cell precursor
acute lymphoblastic leukemia; RNA-seq: RNA-
sequencing; pos: positive; neg: negative; EV:
empty vector; C+: positive control.
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the next day and one-half volume media changes were performed
every other day thereafter. Hematopoietic differentiation was
assessed by flow cytometry at day 9 of co-culture. Accordingly,
hESC-OP9 co-cultures were treated with collagenase IV/TrypLE
and cells were dissociated and filtered through a 70-mm strainer.
Cell suspensions were stained with anti-mouse CD29-FITC and
anti-human CD34-PE and CD45-APC antibodies. The proportion
of HEP (CD34+CD31+CD45-) and total blood cells (CD45+) were
analyzed within the CD29- hESC-derived cell population.
Hemogenic and endothelial HEP were distinguished based on
CD34 and CD43 expression.40
Culture of FACS-isolated hemato-endothelial 
precursors in MS5 stroma or liquid culture
Day 9 human hESC-OP9 co-cultures were dissociated as above
and both CD45+ cells and HEP were analyzed. FACS-purified HEP
(CD29-CD34+CD31+CD45-) were plated onto MS5 stroma or in
liquid culture for 30 or 16 days, respectively, in differentiation
medium with hematopoietic cytokines (50 ng/mL stem cell factor,
50 ng/mL Flt3L, 10 ng/mL interleukin-3, 20 ng/mL interleukin-7).
The medium was changed every 7 days, and the emergence of
CD45+ hematopoietic cells was analyzed by FACS.
Endothelial differentiation of hemato-endothelial 
precursors 
HEP (2×104) from day 9 human hESC-OP9 co-cultures were
seeded onto 0.1% gelatin-coated plates in complete EGM-2 medi-
um with microvasculature supplements (Lonza) for 7 days. Cells
were then fixed, permeabilized and stained with rabbit anti-
human VE-cadherin (Cayman), mouse anti-human endothelial
nitric oxide synthase (BD Biosciences), and mouse anti-human
von Willebrand factor (DAKO) followed by Alexa 488-conjugated
anti-rabbit or Cy3-conjugated anti-mouse (Jackson
Immunoresearch) antibodies. Nuclei were counterstained with
4′,6-diamidino-2-phenylindole. Images were obtained using an
inverted fluorescence microscope. Day 7 differentiating cells were
trypsinized and cell suspensions were stained with anti-human
CD31-FITC and CD144-PerCP-Cy5.5 antibodies.
Mouse transplantation and analysis of 
hematopoietic-endothelial engraftment 
NOD/LtSz-scid IL-2Rg−/− (NSG) mice were housed under sterile
conditions. The Animal Care Committee approved all mouse pro-
tocols. Briefly, cord blood-derived CD34+ hematopoietic stem and
progenitor cells (3×104 cells) or cells from day 15 EB (5×105 cells)
were transplanted into the bone marrow as described previously.49
Animal health was monitored throughout the entire experiment.
Mice were killed 10 weeks after transplantation and cell suspen-
sions were analyzed by FACS for human chimerism using anti-
HLA-ABC-FITC, anti-CD31-PE, CD144-PerCP-Cy5.5, and anti-
CD45-APC antibodies.
RNA- and chromatin immunoprecipitation-sequencing
Details of the RNA- and chromatin immunoprecipitation-
sequencing and analysis are provided in the Online Supplementary
Methods.
Statistical analysis
All data are expressed as mean ± standard error of mean.
Statistical comparisons were performed using GraphPad Prism
software with the nonparametric Mann-Whitney test, two-tailed
P-value (with 95% confidence interval). Statistical significance
was defined as a P-value <0.05.
Results
Co-expression of A4M and MA4 does not hijack
pluripotency
We showed very recently that only 45% of t(4;11)+ B-
ALL patients express the reciprocal fusion A4M, whereas
MA4 is consistently expressed in all t(4;11)+ B-ALL
patients (Figure 1A).18-20 Here, we generated transgenic
hESC lines expressing “MA4 alone”, “A4M alone” or
MA4+A4M (double fusion), (Figure 1B and Online
Supplementary Figure S1B). EV (control)- and MA4-hESC
were established by G418 selection.9 G418-resistant EV- or
MA4-expressing hESC were then transduced with
A4M/dTo-expressing lentiviruses and greater than 90%
transduction efficiency was achieved. Transgenic hESC
lines were maintained for more than 50 passages and
retained hESC-like morphology (Figure 1B, left), transgene
expression (Figure 1B, right), and expression of pluripoten-
cy-associated transcription factors (Figure 1C) and surface
markers (Figure 1D). All hESC genotypes formed ter-
atomas in NSG mice (data not shown).9,50 Thus, (co-)expres-
sion of A4M and/or MA4 is compatible with hESC
pluripotency.
A4M and MA4 co-operate to promote emergence 
of hemato-endothelial precursors and enhance 
blood production
Hematopoietic differentiation was assessed using two
distinct and well-established differentiation systems: EB
formation43,47 (Figure 2) and OP9 co-culture47,48 (Figure 3).
During differentiation, a population of primitive HEP aris-
es, which is responsible for further hematopoietic and
endothelial commitment10,30 (Figures 2A and 3A). We
investigated whether co-expression of A4M and MA4
affects hESC-derived hematopoiesis by analyzing the
emergence of HEP during EB development in hESC indi-
vidually expressing the single fusions or the double fusion.
We observed a pronounced (~5- to 10-fold; P<0.05)
increase in HEP at days 7 and 10 of development in EB
expressing the double A4M and MA4 fusion over those
expressing single fusions (Figure 2B, upper-left panel). We
next assessed whether co-expression of A4M and MA4
influences subsequent hematopoietic commitment of
HEP. The kinetics of emergence and output of both total
CD45+ hematopoietic cells and CD45+CD34+ hematopoi-
etic progenitors was faster (EB day 10) from double
fusion-expressing hESC than from equivalent single
fusion-expressing cells, achieving a 2- to 3-fold higher
hematopoietic output by day 15 of EB development
(Figure 2B). Furthermore, double fusion-expressing HEP
massively accelerated (EB day 10) the emergence of clono-
genic hematopoietic progenitors as compared to single
fusion-expressing HEP (Figure 2B, bottom-right panel).
According to our previous work, if the kinetics of human
EB differentiation is extended, allowing for a continuum
of HEP-to-blood transition, MA4-expressing human EB
display enhanced HEP production coupled to impaired
blood output (EB day 20) (Online Supplementary Figure S2A)
and clonogenic potential (EB day 15) (Figure  2B). We con-
firmed stable expression of ectopic MA4 and A4M upon
EB differentiation, supporting the link between genotype
and phenotype (Figure 2C). 
We also investigated hematopoietic differentiation
using the OP9 differentiation system (Figure 3A,B), and by
plating FACS-sorted HEP in either hematopoietic liquid
C. Bueno et al.
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culture (Figure 3C) or onto MS5 feeders (Figure 3D). After
10 days on OP9 stroma, double fusion-expressing hESC
yielded a 10-fold higher number of CD45+ hematopoietic
cells than did single fusion-expressing hESC (Figure 3B).
Moreover, when HEP were FACS-sorted from day 9 OP9
co-cultures and allowed to differentiate into CD45+ blood
cells, the yield of CD45+ cells was up to 60-fold higher in
double fusion-expressing HEP than in single fusion-
expressing HEP (Figure 3C,D). Encouraged by these
results, we next investigated whether ectopic expression
AF4-MLL in human embryonic hematopoietic development
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Figure 2. A4M cooperates with MA4 to accelerate human embryonic stem cell/erythroid body specification towards hemato-endothelial precursors and subse-
quent hematopoietic differentiation. (A) Schematic of erythroid body hematopoietic differentiation of human embryonic stem cells (hESC) and end-point analyses.
(B) Upper left, specification into hemato-endothelial precursors (HEP; CD31+CD34+CD45-) is accelerated in double fusion-expressing hESC. Subsequent differentia-
tion of HEP into hematopoietic progenitors (upper right) and mature CD45+ blood cells (bottom left) is enhanced in double fusion-expressing HEP. Bottom right,
Colony-forming unit read-out and scoring (pie charts) confirming accelerated and enhanced hematopoietic progenitor potential from double fusion-expressing blood
derivatives. (C) Reverse transcriptase polymerase chain reaction analysis confirming stable expression of MA4 and A4M upon erythroid body differentiation. (D)
Neither MA4- nor double fusion-expressing blood derivatives display in vivo hematopoietic engraftment potential in irradiated NSG mice. Data are presented as mean
± standard error of mean from at least three independent experiments. *P<0.05. EB: erythroid body; bFGF: basic fibroblast growth factor; BMP4: bone morphogenet-
ic protein-4; SCF: stem cell factor; IL: interleukin; G-CSF: granulocyte colony-stimulating factor; CFU: colony-forming unit; EV: empty vector; IBMT; intra-bone marrow
transplantation; C+: positive control; CB: cord blood.
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of both A4M and MA4 confers in vivo engraftment capac-
ity to hESC-derived hematopoietic derivatives. To do this,
we transplanted 5×105 hESC hematopoietic derivatives
from each genotype into myeloablated NSG mice,4,43,47
finding that, despite regulating hematopoietic develop-
ment in vitro, double fusion-expression did not confer in
vivo engraftment to hESC hematopoietic derivatives
(Figure 2D).  
The increased hematopoietic output of double fusion-
expressing hESC might be the consequence of transgene-
mediated proliferation/survival of the emerging HEP or
CD45+ cells. To address this, we analyzed cell cycle distri-
bution (Online Supplementary Figure S2B) and apoptosis
(Online Supplementary Figure S2C) within both HEP and the
CD45+ cell population. No differences in the proportions
of either cycling HEP or CD45+ cells were detected
between genotypes (25–36% for HEP and 35–41% for
CD45+ cells) (Online Supplementary Figure S2B). Apoptotic
levels were similarly low in the different genotypes of
HEP (6–8%) and CD45+ cells (5–7%) (Online Supplementary
Figure S2C). Collectively, these results show that A4M
cooperates with MA4 to induce HEP specification and
blood commitment, without hijacking proliferation or sur-
vival of HEP.
A4M and MA4 cooperate to enhance endothelial cell
fate from hemato-endothelial precursors
We next addressed the developmental impact of A4M in
endothelial maturation from HEP.10,47 We hypothesized
that co-expression of A4M and MA4 in HEP may con-
comitantly promote subsequent endothelial and
hematopoietic commitment or skew the hemato-
endothelial commitment in favor of hematopoiesis. To
test this, we analyzed the ability of HEP to differentiate
into mature endothelial cells. OP9-hESC co-cultures were
dissociated on day 9 of development and HEP were FACS-
sorted and cultured for 1 week in endothelial-promoting
conditions (Figure 4A). The expression of the mature
endothelial markers VE-cadherin (CD144), von
Willebrand factor, endothelial nitric oxide synthase and
CD31 was then analyzed. Irrespective of the genotype,
HEP cultured in endothelial conditions attached, became
spindle-shaped, and formed VE-cadherin+ endothelial-like
structures co-expressing endothelial nitric oxide synthase,
von Willebrand factor and CD31 (Figure 4B,C, top panel).
However, double fusion-expressing HEP were more prone
to differentiate into mature endothelial cells than were
single fusion-expressing HEP. Accordingly, they yielded a
20-fold higher number of VE-cadherin+ endothelial-like
structures (Figure 4C, top panel) and CD144+CD31+
endothelial cells (Figure 4C, bottom panel). Interestingly,
endothelial cells (HLA.ABC+CD31+CD34+CD144+CD45-
CD43-) were found in the bone marrow of mice trans-
planted with double fusion-expressing hESC blood deriv-
atives at levels ~4-fold higher than those in mice trans-
planted with single fusion-expressing cells (Figure 4D).
Within CD34+CD31+CD45- HEP, two subpopulations of
phenotypically and functionally distinct HEP can be dis-
tinguished based on the expression of CD34 and CD43:
hemogenic HEP (CD34low/+CD43+CD45-) and endothelial
HEP (CD34++CD43-CD45-) (Figure 5A).40,48,51 We thus ana-
lyzed the contribution of both HEP populations to the
superior hematopoietic and endothelial differentiation
observed in double fusion-expressing HEP. Co-expression
of A4M and MA4, but not single fusions, robustly
enhanced the emergence of both endothelial and
hemogenic HEP (Figure 5B,C). The identity of hemogenic
and endothelial HEP was confirmed by the specific
C. Bueno et al.
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Figure 3. Co-expression of MA4 and A4M enhances hematopoietic differentiation of human embryonic stem cells in OP9 co-culture. (A) Experimental design of
OP9-based human embryonic stem cell (hESC) differentiation towards hemato-endothelial precursors (HEP) and further hematopoietic commitment of HEP main-
tained in either liquid culture for 16 days or in MS5 co-culture for 30 days. (B) Frequency of total CD45+ blood cells after 9 days in OP9 co-culture. (C,D) CD45-
CD31+CD34+ HEP were FACS-purified at day 9 of OP9 co-culture and allowed to differentiate into CD45+ cells in liquid culture (C) or in MS5 co-culture (D). Data are
represented as the mean ± standard error of mean from independent experiments. bFGF: basic fibroblast growth factor; MTG: monothioglycerol; SCF: stem cell factor;
IL: interleukin; G-CSF: granulocyte colony-stimulating factor; EV: empty vector. 
A
B
C
D
expression of early hematopoietic and endothelial master
genes (Figure 5D). Thus, A4M cooperates with MA4 to
promote hematopoietic and endothelial cell fate.
Genome-wide transcriptomic and H3K79 methylation
profiles support the developmental cooperation
between A4M and MA4
To identify patterns of gene expression that might pro-
vide a molecular explanation of the functional cooperation
between A4M and MA4 in hematopoietic specification,
we performed RNA-sequencing analysis on FACS-purified
EV-, MA4-, A4M- and double fusion-expressing HEP from
day 15 EB. Figure 6A shows a heatmap representation of
the hierarchical clustering of the 335 genes differentially
expressed between the four genotypes (Online
Supplementary Table S2). There is a clear transcriptomic
transition towards a hematopoietic/endothelial gene sig-
nature from EV-HEP to double fusion-expressing HEP.
Single fusion-expressing HEP clustered interspersed
between EV and double-fusion HEP. The biological func-
AF4-MLL in human embryonic hematopoietic development
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Figure 4. Enhanced endothelial cell fate from hemato-endothelial precursors co-expressing MA4 and A4M. (A) Scheme of hemato-endothelial precursor (HEP)
endothelial differentiation and phenotypic characterization. (B) FACS-sorted HEP from day 9 human ESC-OP9 co-cultures were cultured in EGM2 medium for 5 days
and analyzed by immunofluorescence for VE-cadherin, endothelial nitric oxide synthase and von Willebrand factor. (C) Top, Endothelial-like structures were identified
and quantified based on VE-cadherin staining (white dotted-lined areas in B, top panel). Bottom, Frequency of CD45-CD31+CD144+ endothelial cells quantified by
flow cytometry. (D) In vivo endothelial engraftment potential (HLA.ABC+CD31+CD144+CD45-) analyzed in bone marrow of NSG mice 8 weeks after transplantation of
HEP. Data are presented as mean ± standard error of mean from five independent experiments. *P<0.05. bFGF: basic fibroblast growth factor; EV: empty vector;
CB: cord blood.
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tions affected by genes differentially expressed in MA4-,
A4M- and double fusion-expressing HEP relative to EV
were classified by Ingenuity Pathway Analysis soft-
ware;47,52 the top significantly enriched functional cate-
gories included “hematological system development and
function”, “cancer” and “hematological disease” (Figure
6B). Statistical (-logp-value) power shows distant effects of
MA4 and A4M; however, co-expression of both fusions
seems to establish a molecular balance/developmental
cooperation in promoting blood-endothelial specification
from hPSC. Strikingly, biofunctions specifically associated
with hematologic lymphoid malignancies (not with non-
hematologic cancer) were predicted to be activated (posi-
tive z-score) exclusively in double fusion-expressing HEP,
further suggesting a molecular cooperation between MA4
and A4M in development and infant leukemia. (Figure
6C).
The C-terminal partners of MLL fusions normally inter-
act with the histone methyltransferase DOT1L, which is
the sole histone methyltransferase catalyzing histone 3
lysine 79 (H3K79) methylation, a chromatin modification
widely associated with the dysregulated expression of
HOX-A cluster genes in MLL leukemias.13,53 We thus per-
formed genome-wide chromatin immunoprecipitation-
sequencing analysis of the H3K79 trimethylation
(H3K79me3) profiles in control, MA4-, A4M- and double
fusion-expressing hESC-derived blood derivatives (Figure
7, Online Supplementary Figure S3A, Online Supplementary
Table S3). In line with the RNA-sequencing data, function-
al analysis of the differential H3K79me3 peaks specific for
double fusion-expressing cells revealed significant gene
ontology functional categories associated with ”definitive
hematopoiesis”, “myeloid and erythroid
differentiation/homeostasis” and “endothelial cell devel-
opment” (Figure 7A, Online Supplementary Figure S3B).
This further supports the developmental co-operation
between A4M and MA4 in promoting hemato-endothelial
specification.
Finally, we analyzed the H3K79me3 profiles at genomic
loci of the classical MLL target genes reported by
Guenther et al.54 Non-HOX-A classical MLL targets such as
RUNX1, LMO2, ADMA10, and KDM6A showed a slight
although non-significant, enrichment of H3K79me3 in
MA4-expressing hESC, validating our chromatin
immunoprecipitation-sequencing approach (Figure 7B).
However, enrichment of H3K79me3 in HOX-A cluster
genes was observed exclusively in A4M-expressing cells
although it was statistically significant only in double
C. Bueno et al.
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Figure 5. Co-expression of MA4 and
A4M significantly enhances the emer-
gence of both endothelial and
hemogenic hemato-endothelial precur-
sors. (A) Representative flow cytometry
analysis of hemato-endothelial precur-
sors (HEP) with hemogenic (CD45-
CD31+CD43+CD34dim/+) and endothelial
(CD45-CD31+CD43-CD34++) potential.
(B,C) A4M co-operates with MA4 to
boost the emergence of both endothe-
lial (B) and hemogenic (C) HEP. Data are
presented as the mean ±  standard
error of mean from three independent
experiments. (D) Expression of RUNX1c
and Ve-Cad in hemogenic and endothe-
lial HEP. *P<0.05. EB: erythroid body;
EV: empty vector.
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fusion-expressing differentiating hESC (false discovery
rate <0.1) (Figure 7C). As such, HOX-A genes were upreg-
ulated in double fusion-expressing hematopoietic clono-
genic progenitors (Online Supplementary Figure S3C). No
differential enrichment of the repressive H3K4me2/3
mark was observed in either HOX-A or non-HOX genes in
double fusion-expressing cells (Online Supplementary Figure
S4). Collectively, these data suggest that the deregulated
expression of HOX-A genes in MLL leukemias may be
imposed by the reciprocal A4M fusion through H3K79
methyltransferase activity. In support of this, a recent
RNA-sequencing study performed in 42 infants with
t(4;11)+ B-ALL enrolled in the Interfant treatment protocol,
revealed that 45% of t(4;11)+ patients express the A4M
AF4-MLL in human embryonic hematopoietic development
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Figure 6. Transcriptional transition towards a hematopoietic/endothelial gene signature in double fusion-expressing hemato-endothelial precursors. (A) Heatmap
representation of hierarchical clustering of genes differentially expressed between empty vector (EV)-, single fusions- and double fusion-expressing hemato-endothe-
lial precursors (HEP). Each column represents a technical replicate from three independent experiments. (B,C) Statistically significant functional categories (B) and
cancer/leukemia-associated biofunctions (C) identified using Ingenuity Pathway Analysis on genes differentially expressed in single fusions-, and double fusion-
expressing HEP relative to EV. They are ranked by z-score. Functional categories associated with “hematological system development and function” and “cardiovas-
cular system development” are shown in bold. All significant biofunctions are associated with blood cell differentiation, homeostasis and migration/movement.
A
B C
fusion, and that HOX-A cluster genes are exclusively
expressed in this AF4-MLL-expressing subgroup of t(4;11)+
patients, who do in fact have a significantly more favor-
able clinical outcome.19
Discussion
From etiological and pathogenic standpoints, infant
cancer is distinct from adult cancer and should be studied
as a developmental disease.4,7,16 A biologically and clini-
cally intriguing infant cancer is the t(4;11)+ B-ALL, which
is associated with a dismal outcome.4,21,23 Evidence in sup-
port of its prenatal origin comes from studies in monozy-
gotic twins and archived blood spots, providing com-
pelling evidence of a single prenatal cell as the origin for
t(4;11),5 and also from recent genome-wide studies
demonstrating that this infant leukemia has one of the
lowest frequencies of somatic mutations of any
sequenced cancer.55 The stable genome of these patients
suggests that in infant developmental cancer, one “big-
hit” might be sufficient to cause overt disease, support-
ing a key contribution of the prenatal cell-of-origin dur-
ing a critical developmental window of stem cell vulner-
ability in leukemogenesis. However, despite its aggres-
siveness and short latency, our current understanding
about its etiology, pathogenesis and cellular origin is still
limited.2,4,14,16,52 Importantly, a recently developed
xenograft model which represents the most bona fide
model for t(4;11)+ B-ALL so far, has revealed the instruc-
tive role of MLL-Af4 in cord blood-derived CD34+ cells.14
Studies using primary cells from t(4;11)+ B-ALL patients
are incapable of addressing the developmental genesis of
the hematopoietic system. Recent data suggest that fetal
liver lymphoid-primed multipotent progenitors may pro-
vide the developmental prerequisites for the initiation of
t(4;11)+/MLL-AF4 infant leukemia.56 Because leukemogen-
esis manifests as a blockage or altered cell differentiation,
the hematopoietic differentiation of hESC may represent
a promising in vitro model for studying the onset of
hematopoiesis and the earliest events leading to the spec-
ification of the hematopoietic cells.36 Previous studies have
addressed the oncogenic role of leukemic fusion genes in
hESC-derived hematopoiesis.57-59 We previously explored
the developmental impact of the prenatal fusion MA4 in
hESC hemato-endothelial development,10 and found that
MA4 expression promotes the emergence of endothelial-
primed HEP and further endothelial commitment, but
hijacks the specification of hemogenic-primed HEP,
impairing hematopoietic output.10
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Figure 7. H3K79 methylation profiles at genomic loci of MLL targets in MA4-, A4M- and double fusion-expressing human embryonic stem cell-derived blood deriv-
atives. (A) Gene ontology enrichment of differential H3K79me3 peaks specific for double fusion-expressing cells. (B,C) Representative profiles for chromatin immuno-
precipitation-sequencing using anti-H3K79me3 antibody at genomic regions of typical non-HOXA (B) and HOXA MLL targets (C).
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The functional and molecular contribution of the recip-
rocal fusion genes resulting from the derivative translocat-
ed chromosomes remains obscure in cancer.18,60 The MA4
fusion is always expressed in t(4;11)+ B-ALL patients,
whereas the reciprocal fusion A4M is expressed in only
45-50% of the patients.18-20,60 Here, we took advantage of
well-established hESC-based differentiation systems to
study whether the A4M fusion cooperates with MA4 dur-
ing early human hematopoietic and endothelial develop-
ment. Co-expression of A4M and MA4 strongly promoted
the emergence of both endothelial-primed and
hemogenic-primed HEP. Moreover, the double fusion-
expressing HEP specified into significantly higher num-
bers of both hematopoietic and endothelial cells, irrespec-
tive of the in vitro differentiation protocol used and with-
out affecting survival or proliferation, indicating a func-
tional (developmental) cooperation between MA4 and
A4M fusions during human hematopoietic development.
This notion was confirmed by genome-wide transcrip-
tomic analysis of differentiating HEP. These developmen-
tal biology studies support previous evidence suggesting
that A4M contributes to the pathobiology of t(4;11)+ B-
ALL. Accordingly, Bursen et al.11 reported that A4M-trans-
duced murine hematopoietic stem cells developed pro-B-
ALL, whereas co-transduction with MA4 and A4M result-
ed in mixed lineage leukemia. Moreover, studies from
Milne’s laboratory demonstrated that RUNX1 is directly
activated by MA4 and the RUNX1 protein interacts with
the A4M protein, suggesting a mechanism of cooperation
between the two fusion genes at the molecular level.25
In the embryo, definitive hematopoiesis cannot occur in
the absence of endothelial cell development. Definitive
hematopoietic stem cells in both mice and humans
emerge from the hemogenic endothelium by a process
known as endothelial-to-hematopoietic transition.61
Hematopoietic differentiation of hESC occurs through the
generation of HEP, from which both endothelial and
hematopoietic cells then originate. Here, co-expression of
A4M and MA4 in HEP concomitantly promoted endothe-
lial and hematopoietic commitment rather than skewing
the hemato-endothelial commitment in favor of one line-
age over the other. This finding is important because
beyond its pathogenic role in acute leukemias, the MLL
gene is implicated in endothelial cell maturation, and
endothelial dysfunction was recently linked to disease
outcome in childhood leukemias.31,32 Furthermore, other
leukemia fusion oncogenes as well as lymphoma-specific
genetic aberrations have been found in endothelial cells
from patients with chronic myeloid leukemia and B-cell
lymphoma,10,43,44 suggesting that endothelial cells may be
part of the neoplastic clone. In addition, bone marrow-
derived mesenchymal stem cells from infant t(4;11)+ B-cell
ALL were recently found to harbor and express the t(4;11)
translocation.33 The existence of a common embryonic
precursor for mesenchymal stem cells and endothelial cells
has been recently demonstrated by hESC-directed differ-
entiation.10,45 The finding of such a common embryonic
precursor, and the presence of t(4;11) in both leukemic
blasts and bone marrow mesenchymal stem cells of infant
patients, suggests that the t(4;11) translocation arises and
has a developmental impact on early pre-hematopoietic
precursors. As a technical caveat, it is important to empha-
size that MA4 and A4M were sequentially transduced to
allow for antibiotic selection and homogeneously-trans-
duced hESC cultures. However, in double fusion-express-
ing differentiating blood cells, MA4 was never individual-
ly expressed in the absence of A4M. When hematopoietic
differentiation of hESC was induced by EB formation both
fusions were readily co-expressed, ruling out a biased
functional phenotype driven by the sequential expression
of each transgene in distinct developmental windows.
Mechanistically, a putative function of A4M is to acti-
vate chromatin, rendering a chromatin landscape similar
to that present during stem cell development. It is current-
ly unknown how A4M is able to reprogram chromatin,
but it does contain the SET domain disrupted from its
"specification domain", the N-terminal portion of MLL,
which binds to MEN1 and LEDGF, shaping the gene tar-
geting module of the MLL gene. When A4M is expressed,
the N-terminal portion is substituted by the AF4 N-termi-
nus, which is the crucial domain (AF4N) that binds to and
strongly activates RNA polymerase II (RNAP II) for tran-
scriptional elongation. Overexpression of either AF4,
AF4N or the fusion protein A4M induces robust RNAP II-
dependent gene transcription by overwriting the elonga-
tion control process in a dominant fashion.62-64 Since gene
transcription per se and in particular “sterile” transcription
is a powerful mechanism for chromatin activation, A4M
could potentiate MA4 to skew normal and leukemic
hematopoietic cell fate decisions. This also explains why
MA4 has a more prominent role in the disease than the
reciprocal A4M. If A4M functioned to initiate this process
only by itself, then it would become obsolete after fulfill-
ing the "chromatin opening job". However, transcription
factors such as MA4, RUNX1 or others then establish the
transcriptional program leading to leukemogenesis. This is
reflected in the enhanced hematopoietic potential of dou-
ble fusion-expressing hESC and the enriched H3K79me3
activation mark in HOX-A cluster genes exclusively when
MA4 and A4M are co-expressed. Thus, A4M prepares
other transcription factors to become oncoproteins.
Molecularly, C-terminal-partners of MLL fusions (AF4,
AF9, ENL) interact with DOT1L, which is the sole histone
methyltransferase catalyzing H3K79 methylation, a chro-
matin modification widely associated with the dysregulat-
ed expression of the HOX-A gene cluster in MLL-
rearranged leukemias.13,53 Here, chromatin immunoprecip-
itation-sequencing analysis of differentially enriched
H3K79me3 genomic regions confirmed a
hematopoietic/endothelial cell differentiation signature in
double fusion-expressing HEP, and revealed a significant
enrichment of H3K79 methylated regions specifically
associated with HOX-A cluster MLL target genes (but not
with non-HOX-A MLL targets) in double fusion-express-
ing differentiating hematopoietic cells. This is in line with
the recently found significant positive correlation between
the upregulation of the HOX-A gene cluster and the
expression of A4M in primary t(4;11)+ infant B-cell ALL
samples, and with previous studies identifying that
approximately one-half of t(4;11)+ patients do not have an
activated HOX-A signature.20,65,66 This may explain why
MA4 failed recently to bind to HOX-A genes to regulate
HOXA gene expression.14 Collectively, MA4 and A4M
might cooperate through a complex molecular interaction
to control HOX-A gene regulation.25 In conclusion, we
describe a functional and molecular cooperation between
MA4 and A4M fusions during human hematopoietic
development, and demonstrate how hESC-based
hematopoietic differentiation represents a promising sys-
tem to explore the developmental impact of the chimeric
AF4-MLL in human embryonic hematopoietic development
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proteins resulting from chromosomal translocations,
which remains obscure in human leukemia.
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